HANNOVER, Germany, Jan. 18 /PRNewswire/ -- Digilab, Inc. is pleased to announce a Notice of Allowance has been issued for novel Alzheimer’s biomarkers discovered and identified with its proprietary Peptidomics(R) technologies. A total of 312 cerebrospinal fluid samples from patients suffering from Alzheimer’s Disease, primary dementia disorder, or cognitively unimpaired subjects were collected and analyzed. A series of peptides was identified that differentiated between Alzheimer patients and both the dementia subjects and the subjects with normal cognitive profiles. These highly reliable biomarkers provide the basis for early differentiation between patients with Alzheimer’s related dementia and subjects without cognitive impairment, demonstrating the selective power and specificity of peptides as biomarkers.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/CLTH011LOGO )
David Giddings, Digilab Inc. President and CEO, commented: “The strength and robustness of Digilab’s ISO certified technology and processes has once again demonstrated the ability to discover and identify novel endogenous peptide biomarkers of high relevance to therapeutic discovery and development. Alzheimer’s is a disease that will continue to grow in importance as the bulge of baby boomers approach the age where this disease is manifested. Historically, this devastating disease has been addressed reactively as there are no reliable diagnostics for the early detection and proactive management of Alzheimer’s. Digilab is pleased to offer these highly qualified biomarkers for collaborative development or out-licensing in support of clinical development of both diagnostic and therapeutic products.”
About Digilab
As a global leader in Peptidomics(R) for the discovery of peptide biomarkers, Digilab develops innovative and differentiated products and services for the life sciences research and in-vitro diagnostics markets. The company’s pioneering work for the U.S. Government in 1969 led to the development, manufacture, sales and service of the first commercial Fourier- Transform InfraRed (FTIR) spectrometer. In the fall of 2004, Digilab sold its FTIR molecular spectroscopy assets to Varian Inc. Since then, the company has remained focused on novel and proprietary sample prep, bioinformatics, and spectroscopy detection/analysis devices which can be integrated into solutions for research and diagnostics applications.
In February 2006 Digilab acquired BioVisioN, AG in Hannover, Germany. Digilab is globally commercializing Digilab BioVisioN GmbH’s patented Peptidomics(R) products and services and generating IP in this space. Digilab works with companies from the pharmaceutical and diagnostics sectors; analytical instrumentation hardware, software, and consumables suppliers; and academic institutions and government agencies.
For more information contact: Leif Honda, Director of Business Development at lhonda@digilabglobal.com, (781) 575-0310 or visit http://www.peptidomics.com .
Photo: http://www.newscom.com/cgi-bin/prnh/20061221/CLTH011LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comDigilab, Inc.
CONTACT: Leif Honda, Digilab, Inc. Director of Business Development,+1-781-575-0310, or lhonda@digilabglobal.com
Web site: http://www.peptidomics.com/
